Australia's Biota CEO Defends Firm's Relenza Decline In Recent Quarter
This article was originally published in PharmAsia News
Executive SummaryThe head of Australia's Biota responded angrily to the stock market's negative response to his company's recent sales figures
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.